Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
The Third People's Hospital of Chengdu
600 participants
Oct 24, 2023
OBSERVATIONAL
Conditions
Summary
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity. The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.
Eligibility
Inclusion Criteria3
- Patients aged 18 years or older who provided written informed consent
- Patients who schedule to undergo bariatric surgery and a liver biopsy (LB) for the investigation of suspected MASLD
- Patients who schedule to undergo FibroScan examination
Exclusion Criteria8
- Patients with ascites or pregnant women
- Patients with any active implantable medical device (such as a pacemaker or defibrillator)
- Patients who have undergone liver transplantation
- Patients with cardiac failure and/or significant valvular disease
- Patients with haemochromatosis
- Patients who have refused to undergo LB or blood tests
- Patients with a confirmed diagnosis of active malignancy, or other terminal disease
- Patients participating in another clinical trial within the preceding 30 days
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In individuals with obesity, a biopsy is performed within a week after undergoing an FibroScan examination.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06720766